Insulin glargine: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210605's history or Mylan's company page.
On May 17, 2018, FDA declined to approve Insulin glargine (NDA 210605) from Mylan GmbH in its present form, citing clinical-related major deficiencies, product quality-related major deficiencies, human factors-related major deficiencies. The application was later approved.
- Letter date: May 17, 2018
- Application: NDA 210605
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA1. Your 505(b)(2) application requests approval of your proposed insulin glargine product manufactured using Process VI at a facility in Malaysia (i.e., Process VI product), while the proposed insulin glargine product studied in the phase 3 clinical trials was...… openFDA did not return the full text just now. Open it in the letter search.
Other Letters on This Application
- Insulin glargineAug 28, 2019 · NDA 210605 · later approved
Record
- Company
- Mylan GmbH
- Application
- NDA 210605
- Status in openFDA
- Approved
- Review division
- Division of Metabolism and Endocrinology Products
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters